First global patient recruited for rare blood cancer study at King’s

Phase 3TAK-226Positive

AI Analysis

Summary

King's College Hospital NHS Foundation Trust announced the first global patient recruitment for the TAK-226-3001 Phase III trial for rare blood cancer treatment.

Clinical Trial Data

Phase

Phase III

Importance:3/10

Sentiment:

0.50

Phase 3rare diseasehematologic malignancypatient recruitment

Related Companies

$TAK

Read the original article

Published by Clinical Trials Arena on September 8, 2026 10:21 AM

Read Original